newsfilter
← Latest News
GlobeNewswire·

Cerenome Reports Third Quarter 2026 Financial Results and Business Highlights Featuring REYOBIQ ReSPECT- LM Data and CNSide Commercial and Reimbursement Progress

CNSY
  • Cerenome, Inc. (Nasdaq: CNSY) reported third quarter 2026 financial results & outlined recent business progress, including the first quarter of CNSide diagnostic revenue recognition.
  • The company rebranded from Plus Therapeutics to Cerenome in August, with stock trading under the symbol CNSY.
  • Ron Andrews was appointed Chief Business Officer in November to advance CNSide commercial adoption.
  • Q3 2026 net diagnostic revenue totaled $0.7 million, derived from approximately $1.55 million in gross billings.
  • Payer coverage for CNSide expanded to include Medical Mutual, Health Care Service Corporation, Blue Cross Blue Shield of Michigan, Florida Blue, & Aetna, representing ~190 million covered lives.
  • The Aetna agreement, effective November 1, is the first national CNSide payer contract covering both tumor cell enumeration & molecular profiling.
  • CNSide CSF Molecular Profile tests for solid tumors & hematologic malignancies launched on October 12, offering DNA & RNA profiling from cerebrospinal fluid.
  • Medicare reimbursement for CNSide is on track for the first half of 2027, with a coverage determination pursued from Novitas Solutions.
  • REYOBIQ Phase 2 enrollment in recurrent glioblastoma (ReSPECT-GBM) was completed in October, with topline data expected in mid-2027.
  • REYOBIQ Phase 1 multi-dose findings (ReSPECT-LM) showed no dose-limiting toxicities or treatment discontinuations in the first 10 patients treated with repeated intraventricular doses.
  • Preclinical data presented in October suggested REYOBIQ may enhance antitumor activity when combined with anti-PD-1 checkpoint blockade.
  • Cash, cash equivalents, & investments stood at $4.9 million as of September 30, 2026, following a $20 million senior secured financing facility closing.
  • The company raised an additional $3.8 million under its Equity Distribution Agreement subsequent to the quarter end.
  • Q3 2026 operating loss was $7.5 million, with a net loss of $8.7 million ($1.14 per share), compared to a net loss of $4.4 million a year earlier.
  • Upcoming milestones include expanding CNSide commercial rollout & continuing dose escalation for REYOBIQ while awaiting mid-2027 trial readouts.
Company
Cerenome, Inc.
Keywords
Nasdaq:CNSY, Cerenome, Inc.